Navigation Links
PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
Date:12/13/2007

MONTEREY, Calif., Dec. 13 /PRNewswire/ -- PARI's eFlow, an advanced electronic nebulizer, was optimized and used to deliver Alnylam's ALN-RSV01 in a Phase I human clinical trial. Results of the Phase I trial were announced today at the 18th Annual Drug Delivery to the Lungs meeting held in Edinburgh, U.K. ALN-RSV01 is an RNAi therapeutic being developed as a treatment for respiratory syncytial virus (RSV) infection, the leading cause of pediatric hospitalization in the U.S. and a prevalent infection in immune-compromised adults. RSV currently does not have a viable treatment option. The Phase I study represents the first-ever clinical study of an RNAi therapeutic administered via inhalation.

"With the flexibility of the eFlow platform, we are collaborating with a number of pharmaceutical companies to develop new respiratory therapies that are delivered to the lungs in a faster, more effective manner. We hope that working with Alnylam on a treatment for RSV will open up a new treatment option to meet this unmet need," said Geoff Hunziker, President of eFlow LLC.

Alnylam's Phase I study for ALN-RSV01 was a randomized, double-blind, placebo-controlled trial in healthy adult volunteers to assess the safety, tolerability, and pharmacokinetics of ALN-RSV01 administrated by inhalation via nebulizer. All major objectives of the trial were met, including definition of a safe and well-tolerated dose and regimen for advancement of ALN-RSV01 into further Phase II development. Importantly, data showed that the efficiency of delivery of ALN-RSV01 delivered via inhalation, as measured by plasma levels, was significantly greater in humans than observed pre-clinically.

Respiratory syncytial virus (RSV) is a highly contagious virus that causes infections in the upper and lower respiratory tract associated with predictable seasonal outbreaks worldwide. RSV infection is the most common cause for infant hospitalization (more than 100,000 hospitalizations annu
'/>"/>

SOURCE PARI Pharma
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Comparison of obstetric outcomes between on-call and patients own obstetricians
2. EDAP Launches Enhanced Communication Plans at SIU Paris Congress
3. Highmark Blue Cross Blue Shield Introduces New Health Plan Comparison Tool for Consumers
4. Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers
5. LOreal Paris Celebrates Ten Years of Hope and Healing
6. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
7. Global Summit on AIDS & The Church Calls for Public, Private and Parish Sectors To Unite in Response to Worldwide Pandemic: Pastor Rick and Kay Warren Host More Than 1,700 at Event Featuring International Dignitaries, Political Figures and International E
8. Laser Energetics Delivers BrightStar(TM) Alexandrite Laser to Fortune 50 Defense Company
9. Lilly Delivers Strong Third-Quarter Results
10. Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007
11. E.D.G.E. in Leadership Study Delivers First-Ever Data on Executive Women in Pharmaceutical and Biotech Industries
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2Reportlinker Adds Emerging Clinical Trial Locations India 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 62397 1Reportlinker Adds Emerging Clinical Trial Locations India 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 62397 2Reportlinker Adds Emerging Clinical Trial Locations India 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 62397 3Reportlinker Adds Emerging Clinical Trial Locations India 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 62397 4Reportlinker Adds Emerging Clinical Trial Locations India 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 62397 5Reportlinker Adds Emerging Clinical Trial Locations India 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 62397 6Reportlinker Adds Emerging Clinical Trial Locations India 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 62397 7Scientist Who Helps Explain Pain Wins Grawemeyer Award 62392 1Scientist Who Helps Explain Pain Wins Grawemeyer Award 62392 2Patient Safety Technologies Inc Appoints Marc L Rose CPA 28PA 29 Chief Financial Officer 6662 1Patient Safety Technologies Inc Appoints Marc L Rose CPA 28PA 29 Chief Financial Officer 6662 2